← Back
$ACRS All transactions

Aclaris Therapeutics, Inc.

F

$ Value

$17K

Shares

4,984

Price

$4

Filed

Feb 3

Insider

Name

Balthaser Kevin

Title

Chief Financial Officer

CIK

0001957554

Roles

Officer

Transaction Details

Transaction Date

2026-02-01

Code

F

Table

Non-Derivative

Ownership

Direct

Equity Swap

No

Shares After

170,179

Footnotes

Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. | The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. | The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.

Filing Info

Accession No.

0001957554-26-000005

Form Type

4

Issuer CIK

0001557746

Balthaser Kevin's History

Date Ticker Type Value
2026-02-03 ACRS M
2026-02-03 ACRS F $22K
2026-02-03 ACRS M $0
2026-02-02 ACRS A $0
2026-02-02 ACRS A $0
2026-02-01 ACRS M
2026-02-01 ACRS F $17K
2026-02-01 ACRS M $0
2026-01-02 ACRS M
2026-01-02 ACRS F $13K

Other Insiders at ACRS (90d)

Insider Bought Sold Last
Walker Neal
CEO
2026-02-03
Loerop James
Chief Business Officer
2026-02-03
Balthaser Kevin
Chief Financial Officer
2026-02-03
Davis Hugh M.
President and COO
2026-02-03
Hall Jesse Wayne
Chief Medical Officer
2026-02-02
Kolbeck Roland Wilhelm
Chief Scientific Officer
2026-02-02